Revolutionizing Oncology Trials in India Through Digital Innovation
In this interview with Dr. Seema Rajsingh, Executive Medical Director and Jarem Edwards, Clinical Scientist – Early Drug Development...
Moe Alsumidaie
Behavioral Science: The Untapped Asset in Obesity Trial Strategy
The global obesity epidemic has shifted from a public health issue to a fiercely competitive pharmaceutical frontier. With GLP-1...
Elevating Clinical Trial Imaging to a First-Class Data Role
In this conversation with Jeffrey Sorenson, CEO at Yunu, we explore the transformative potential of treating imaging data as...
FDA Dropped Diversity But Good Science Depends On It
In this conversation, Thad Wolfram, Chief Strategy Officer of EmVenio Research and PCM Trials, shares his insights on the...
Scaling GenAI in Life Sciences: Overcoming Barriers with Strategy, Compliance, and Human Insight
As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...
Transforming Clinical Trials: Anca Copaescu on Clinical Trial Business Infrastructure, AI, and Vendor Management
In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...
Addressing the 64% Clinical Trial Data Incompleteness Rate in Observational Research
In this interview, Rachael Thomas Higgins, Chief Commercial Officer of PicnicHealth, offers her perspective on the pivotal role of...
Guided, Then Penalized: A Deep Dive into the FDA’s MDMA Ruling and What it Means for Psychedelic Clinical Trials
In August 2024, the FDA rejected the New Drug Application for MDMA-assisted therapy for PTSD, sponsored by Lykos Therapeutics,...
How Cybin is Shifting Psychedelic Clinical Trial Execution and Regulatory Strategy
In the dynamic field of mental health, Cybin is pioneering psychedelic therapies. Amir Inamdar, Cybin’s Chief Medical Officer, discusses...
How FDA’s Guidance on Decentralized Trials Applies to Community-based Research Execution and Compliance
In September 2024, the U.S. Food and Drug Administration (FDA) issued its final guidance titled Conducting Clinical Trials with Decentralized...